Building on a Legacy of Transformation
- What We’ve Accomplished
- Our Current Focus
- Looking Ahead
What We’ve Accomplished
For decades, we have led global virology research, turning once-fatal diseases into manageable or more easily preventable conditions.
From pioneering the first HIV single-tablet treatment regimen to launching the only twice-yearly prevention option, we are setting new milestones in prevention and care with therapies that significantly improve outcomes for individuals living with HIV or at risk for HIV acquisition.
In hepatitis, we developed a cure for hepatitis C, and our therapies helped transform hepatitis B into a more manageable condition. And when the world needed us, we stepped up to deliver the first approved antiviral medicine to treat COVID-19.
These advances were possible thanks to our investment in world-class science, our deep connections with community partners and our long-standing commitment to advancing health and opportunity to all.
Our Current Focus
Today, we’re building on our legacy in virology, developing long-acting and person-centered options for HIV prevention and treatment while working together with community partners to help end the epidemic. At the same time, we're developing new treatments for chronic hepatitis B and D as we work toward the goal of global elimination of hepatitis as a public health threat.
Looking Ahead
We won’t rest until the HIV epidemic has ended for everyone, everywhere. Ultimately, we're working to help develop cures for HIV and hepatitis B, while advancing our preparedness against potential infectious diseases.
At the same time, we recognize that medicines alone won’t lead to the healthier world we envision. We’re committed to working closely with partners to advance health equity and break down the barriers to care that fuel the spread of viruses and affect access to care.
PIPELINE
We have a strong, diverse pipeline and are on track to achieve our 2019 ambition of delivering 10+ transformative therapies by 2030.
Explore Our Pipeline
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We have developed more than 25 life-changing medicines to treat, prevent and transform conditions that impact millions of people and are rapidly growing our portfolio through research, development and external collaborations.
Latest News
Some of the content on this page is not intended for users outside the U.S.
Additional Therapeutic Areas
Oncology
We’re disrupting the status quo in how cancer treatments are developed to accelerate new therapies.
Inflammation
We’re unlocking the next generation of therapies across inflammatory and fibrotic diseases.